药明康德集团 董事长
Dr. Ge Li is one of the most influential leaders in the global biopharma R&D industry. He pioneered an integrated R&D service model and the open-acces...
阅读更多 中国医药创新促进会 执行会长
宋瑞霖，中国政法大学法学学士，中欧国际工商学院工商管理硕士，中国药科大学社会与管理药学博士。现任中国医药创新促进会执行会长、中国药科大学国家药物政策与...
阅读更多 英国生物工业协会（BIA） 首席执行官
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve sought to make the UK life science ecosystem the third global c...
阅读更多 阿斯利康 全球执行副总裁、国际业务及中国总裁
王磊先生现任阿斯利康全球执行副总裁，国际业务及中国总裁，全面负责中国、亚洲国家、澳大利亚、新西兰、拉丁美洲、巴西、俄罗斯、欧亚大陆、中东及非洲市场的整...
阅读更多 药明康德 联席首席执行官
胡正国先生现任药明康德联席首席执行官。作为一位杰出的商业领袖，胡正国先生在公司的运营管理、业务管理和财务管理方面具有丰富的领导经验。自2007年加入药...
阅读更多 英国驻华大使馆 中国区公使衔参赞
何先生拥有牛津大学化学硕士学位和瑞士洛桑国际管理发展学院MBA学位。在跨越七个国家的工作经历中，何先生曾负责管理来自三十多个国家的多语种多元化团队。何...
阅读更多 恒瑞医药 全球研发负责人
张连山博士1982年毕业于南京药学院，现中国药科大学，1992年在德国Tubingen大学获有化学博士。先后在Tubingen大学和美国Vanderb...
阅读更多 通和毓承 创始合伙人兼首席执行官
陈连勇博士于2012年创建通和资本并担任创始合伙人，有20年的从业经验。2017年5月通和资本与毓承资本两支团队合并，组建为一个专注于医疗健康领域的新...
阅读更多 阿斯利康 全球肿瘤研发高级副总裁、中国新药研发总裁
医学博士陈之键自2013年4月起加入阿斯利康中国，现担任全球肿瘤研发高级副总裁兼中国新药研发负责人。陈博士在药物研发领域有15年以上的管理经验，曾就职...
阅读更多 新加坡科技研究局， Experimental Drug Development Centre 首席执行官
Most recently Damian was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Clinical Science...
阅读更多 药明康德 首席商务官
Dr. Steve Yang is Executive Vice President and Chief Business Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. His respons...
阅读更多 Aaron Diamond 艾滋病研究中心 科学主任兼首席执行官
David D. Ho is the founding Scientific Director of the Aaron Diamond AIDS Research Center and the Irene Diamond Professor at The Rockefeller Universit...
阅读更多 德克萨斯大学西南医学中心 主任
Zhijian ‘James’ Chen is an Investigator of Howard Hughes Medical Institute, and Professor in the Department of Molecular Biology at the University of ...
阅读更多 MedImmune研发副总裁， 英国工业协会主席
Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), now the global biologics research and development arm of AstraZeneca, in 1993. An...
阅读更多 高瓴资本集团 合伙人
易诺青先生是高瓴资本集团的合伙人，于公司创立时加入，现负责高瓴资本集团在医疗健康领域的公开市场和非公开市场股权投资。他领导团队成功地投资了多家上市公司...
阅读更多 启明创投 主管合伙人
梁颕宇女士是启明创投领导医疗健康行业投资的主管合伙人。启明目前旗下管理总基金规模超过43亿美元并投资了超过300家创新企业。梁女士被福布斯中国评选为2...
阅读更多 Arsenal Bio 联合创始人及首席执行官
Ken is the CEO and co-founder of Arsenal Bio, a startup focused on synthetic control of the immune system which is based in San Francisco and Los Ange...
阅读更多 国投创新 医疗健康首席科学家
何如意博士在美国FDA具有17年临床审评审批经验, 主管消化系统胃肠道类药物及罕见病药物的临床审评审批工作，曾是美国FDA新药审批办公室消化系统及罕见...
阅读更多 百济神州 创始人、董事长兼首席执行官
John V. Oyler is the Co-Founder, Chief Executive Officer and Chairman of the Board of Directors of BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, comm...
阅读更多 药明生物 质量与全球监管事务副总裁
王刚博士现任药明生物上海质量部副总裁，负责上海药明生物的质量工作和全球监管事务工作。加入药明生物前，王刚博士在美国FDA和CFDA工作13年，先后任C...
阅读更多 药明生物 首席质量官
辛强博士于2018年1月加入药明生物担任首席质量官，在此之前他在美国FDA任职近30年，在生物制品及生物技术药物的CMC（生产过程与控制）和GMP（药...
阅读更多 中国乔治全球健康研究所所长， 新南威尔士大学教授
Dr. Anderson is Executive Director of The George Institute for Global Health in China, Senior Principal Research Fellow of the National Health and Med...
阅读更多 默沙东 全球副总裁、中国研发总经理
作为默沙东全球副总裁及默沙东中国研发总经理，李正卿博士负责北京研发中心的整体运营和战略方向的把控。李正卿博士带领的研发团队肩负着将创新药物和疫苗以最有...
阅读更多 英国国家健康研究所 业务发展主管
The National Institute for Health Research Clinical Research Network is the research delivery arm of the NHS. It invests some £300m each year into an...
阅读更多 亚狮康 首席执行官
Dr. Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Dr. Firth founded ASLAN in 2010 after a career in global pharmaceutica...
阅读更多 歌礼制药 创始人、董事会主席兼首席执行官
吴劲梓博士，歌礼创始人、董事会主席兼首席执行官，于2013年4月创办歌礼。歌礼是一家拥有两个上市产品的研发驱动型创新生物科技公司。2018年8月，在吴...
阅读更多 北海康成 董事长兼首席执行官
Dr. James Xue has spent 20+ years in pharmaceutical industry and is the founder, chairman & CEO of CANbridge Pharmaceuticals Inc., a bio-tech company ...
阅读更多 Insilico Medicine 创始人及首席执行官
Dr. Zhavoronkov is the CEO of Insilico Medicine, a leader in the next-generation artificial intelligence technologies for drug discovery, biomarker de...
阅读更多 BIOAGE 首席运营官、首席医学官
Eric leads BIOAGE’s human cohort partnerships and computational efforts to discover and prioritize drug targets for human aging. Eric was previously a...
阅读更多 ABL Bio 首席执行官
Sang Hoon Lee is the founder and CEO of ABL Bio. Prior to creating ABL Bio, Sang Hoon Lee served as the head of the Bio Division at Hanwha Chemical fr...
阅读更多 暨南大学衰老与再生医学院 院长
主要研究方向：器官衰老的分子机制及干预靶点；成体干细胞衰老和组织器官再生；利用动物模型研究如何延缓衰老延长寿命。主要学术贡献：（1）发现端粒缩短和DN...
阅读更多 aMoon Fund 副总裁
Guy Spigelman is VP of Portfolio Success at aMoon, a Global HealthTech and LifeSciences VC based in Israel with over $800M under management. Previousl...
阅读更多 Carrick Therapeutics 首席科学官及研发负责人
Dr. Bahl has 25 years of international Pharmaceutical experience working to deliver innovation via drug development projects in the US, Japan, and Eur...
阅读更多 中国国家药物（抗肿瘤药）临床研究中心 主任
徐兵河，主任医师，教授，博士生导师。现任国家药物（抗肿瘤药）临床研究中心主任。中国抗癌协会乳腺癌专业委员会第七届主任委员、中国抗癌协会肿瘤药物临床研究...
阅读更多 AZTherapies 总裁兼首席医学官
Karen Reeves, MD is President and Chief Medical Officer at AZTherapies, a start-up company using a multi-action approach to treat Alzheimer’s Disease ...
阅读更多 北京大学深圳研究生院化学生物学与生物技术学院 特聘研究员
1994年毕业于北京大学化学系，1999年获得美国哥伦比亚大学博士学位（导师：Clark Still教授），2002年在斯坦福大学完成博士后研究（导师...
阅读更多 Metabomed 首席执行官
Dr. Botti has been Metabomed's CEO since July 2016. Simone co-founded Metabomed while he was Head of the Israel Bioincubator Fund at Merck Ventures, w...
阅读更多 Vivace Therapeutics 总裁兼首席执行官
Dr. Sofie Qiao is the founding president and CEO of Vivace Therapeutics. Prior to co-founding Vivace, she served as managing director of WuXi ventures...
阅读更多 科望医药 首席执行官
纪晓辉博士为科望医药的联合创始人和CEO。科望医药主要聚焦于开发新一代肿瘤免疫治疗。纪晓辉博士也是礼来亚洲基金的风险合伙人。 在加入礼来亚洲基金前，纪...
阅读更多 克睿基因 首席技术官
林彦妮博士是苏州克睿基因的首席技术官及联合创始人。她致力于应用基因工程学方法, 在新型医药和诊断领域中创造临床和生产流程的解决方案。她有9年以上在哺乳...
阅读更多 Schrödinger 常务董事
Dr. Weiser joined Schrödinger in 2002. He received his doctorate in Organic Chemistry from the Georg-August-University in Göttingen, Germany in 1996. ...
阅读更多 TARA Biosystems 首席执行官
Misti Ushio is the CEO of TARA Biosystems.TARA Biosystems develops physiologically relevant 3D tissue models for drug discovery and development applic...
阅读更多 同济大学生物信息系 教授
刘琦, 同济大学生物信息系教授，博士生导师。IEEE会员，ACM会员，中国计算机协会CCF高级会员（生物信息学专业组委员），中国人工智能学会会员 (生...
阅读更多 Cyclica 总裁兼首席执行官
Naheed Kurji is the President and CEO of Cyclica, a Toronto-based, venture-backed biotechnology company that has recently been named by Deep Knowledge...
阅读更多 Coland Pharmaceuticals 董事长
Willliam Robert Keller joined Roche in Basel 1972 and served from 1974 to 2003 in several marketing and General Manager positions at Roche Group in So...
阅读更多 华领医药 首席执行官
陈力博士，华领医药技术（上海）有限公司董事长、创始人、首席执行官、首席科学官。陈力博士曾任罗氏研发中国有限公司首席科学官，拥有20多年新药研发创新及管...
阅读更多 药明生物 首席执行官
陈智胜博士是香港上市公司药明生物(02269.HK)的首席执行官。在短短七年时间里，他组建了生物医药领域的明星团队创办了一个市值超过100亿美元生物医...
阅读更多 Twist Bioscience 高级副总裁
Ray is a seasoned executive, bringing his unique perspective as a clinician-scientist leading and growing start-up companies. He joins Twist Bioscienc...
阅读更多 强生亚太创新中心 负责人
Dan Wang, MD, is the Head of Johnson & Johnson Innovation, Asia Pacific. In this role, she is responsible for managing a portfolio of co-investments s...
阅读更多 哈佛大学Blavatnik生物医学加速中心 首席科学官
Dr. Curtis Keith has served as Chief Scientific Officer of Harvard University’s Blavatnik Biomedical Accelerator (previously, Harvard Biomedical Accel...
阅读更多 加州大学圣地亚哥分校Rady商学院 院长
Robert S. Sullivan joined the Rady School of Management at UC San Diego as its founding dean in January 2003. Dr. Sullivan is an expert on entrepreneu...
阅读更多 奥博资本 全球合伙人
王健博士是全球最大的专注于生物医疗的投资公司奥博资本（OrbiMed）的合伙人，也是奥博亚洲的创始合伙人。他拥有近30年生物医疗健康领域的投资、创业、...
阅读更多 武田药品工业株式会社，武田湘南健康创新园区 总经理
Toshio Fujimoto, MD, MBA, is the General Manager of Shonan Health Innovation Park (iPark), a science park launched by Takeda Pharmaceutical Company Lt...
阅读更多 默克中国创新中心 董事总经理
孙正洁女士现任默克中国创新中心董事总经理、默克中国战略及转型副总裁，领导集团的战略规划以及默克在中国的创新和数字化转型。孙女士是默克集团战略及转型部全...
阅读更多 高盛集团亚太区（除日本外） 董事长兼行政总裁
贺启新先生是高盛集团亚太区（除日本外）董事长兼行政总裁，同时担任高盛集团管理委员会委员。他亦兼任公司亚太区管理委员会的联席主席。贺启新最初在1991 ...
阅读更多 淡马锡 全球企业发展联席总裁，中国区总裁
吴亦兵先生于2013年10月加入淡马锡，目前担任全球企业发展联席总裁，中国区总裁。在此之前，吴先生于2009年12月起，担任中信产业投资基金管理有限公...
阅读更多 正心谷创新资本 合伙人
林利军先生是一位连续创业的企业家和专业的投资人。31岁从零创立汇添富基金，掌舵中国最优秀的基金管理公司之一的汇添富基金11年。将汇添富基金从中国第47...
阅读更多 ChinaBio 创始人及首席执行官
Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC...
阅读更多 爱康国宾 创始人、董事长兼首席执行官
张黎刚先生是一位在医疗服务与互联网领域的成功创业者，1998年从哈佛大学医学院研宄生部退学回国创业，之后己成功创立了两家美国纳斯达克上市公司。张黎刚先...
阅读更多 北京协和医院 副院长
心血管内科 主任医师 教授 博士生导师北京协和医院副院长中国医学科学院北京协和医学院副院校长国务院政府特殊津贴专家国家卫生计生突出贡献中青年专...
阅读更多 中欧国际工商学院 卫生管理与政策中心主任、经济学教授
蔡江南教授是中欧国际工商学院卫生管理与政策中心主任、经济学兼职教授。他在中国和美国的大学、咨询公司、和政府部门从事了二十多年的卫生经济和卫生政策的教学...
阅读更多 北极光创投 创始人、董事总经理
邓锋先生于2005年创立北极光创投，目前主导管理5支美元基金和5支人民币基金，管理资产逾三百亿人民币，他在高科技，新媒体，清洁技术，消费及健康医疗等领...
阅读更多 美年大健康 董事长
1971 年出生，毕业于上海交通大学电子工程系，上海财经大学金融学硕士，中国中医科学院博士，中欧国际工商管理学院EMBA。美年健康（SZ 002044...
阅读更多 汇桥资本 高级合伙人、董事总经理
李彬博士是汇桥资本LB医疗基金的创始人和首席投资官及汇桥资本集团的合伙人。在此之前，李博士于2008-2015担任国际著名投资银行摩根士丹利的董事总经...
阅读更多 药明康德 高级副总裁、首席战略官
2018年加入药明康德，现任公司首席战略官&高级副总裁。张炜博士有丰富的领导力发展和战略咨询经验，研究新兴市场商业创新，医疗服务的组织与创新和战略变革...
阅读更多 复旦大学附属儿科医院 副院长
周文浩，临床医学博士，主任医师，教授，博士生导师。现任中华医学会儿科分会新生儿学组副组长等职。先后入选教育部“新世纪优秀人才”、“上海市领军人才”、“...
阅读更多 微基因 首席执行官
陈钢博士，WeGene创始人及CEO。WeGene是中国领先的个人基因组和群体基因组学公司。陈钢曾担任香港中文大学兼职助理教授和香港医管局大数据顾问。...
阅读更多 至本医疗科技 创始人、首席执行官
王凯博士是 Origimed 的创始人和首席执行官，致力于为癌症患者提供全面的分子诊断信息，为合作伙伴提供分子病理学和基因组学服务。王凯博士在生物信息...
阅读更多 上海瑞金医院 副院长
宁光，中国工程院院士，教育部长江特聘教授，973首席科学家，上海交通大学博士生导师，上海交通大学医学院附属瑞金医院副院长、卫生部内分泌代谢病重点实验室...
阅读更多 亿康基因 首席执行官
陆思嘉博士毕业于美国哈佛大学，高通量基因测序专家，MALBAC全基因组扩增技术共同发明人，江苏省“双创计划”引进人才，上海市人大代表，上海市“千人计划...
阅读更多 梅奥诊所实验室 总裁
Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester. President, Mayo Clinic Laboratories.Research interests: Lymphoprolifer...
阅读更多 山蓝资本 创始与执行合伙人
发起创办山蓝资本，具有医疗专业基金发起、募资、团队组建、投资、投资后管理等全过程管理经验；具有整个医疗企业创业全过程成功经验：上海微创医疗器械（集团）...
阅读更多 Forbion 管理合伙人
Martien is a Managing Partner at Forbion, a leading European venture capital firm that works closely with entrepreneurs to build life sciences compani...
阅读更多 中国医疗器械行业协会体外诊断分会 理事长
1991.02-1999.4美国库尔特公司 经理1999.07-2003.02上海复星医药（集团）股份有限公司 诊断部总经理2003.03-2016....
阅读更多 药明奥测 首席执行官
刘釜均博士深耕生命科学行业近30年，其中包括20年临床诊断及医疗设备跨国集团的领导经验，在跨文化业务与资源整合，新兴公司业务拓展，国际并购重组及企业管...
阅读更多 丁香园 创始人、董事长
哈尔滨医科大学临床医学本科毕业哈尔滨医科大学肿瘤免疫学硕士毕业2000年创办丁香园，2006年放弃博士学位全职创业。所获荣誉：浙江省健康服务业促进会副...
阅读更多 零氪科技 创始人、首席执行官
2005年毕业于北京邮电大学，2018年毕业于中欧商学院EMBA。先后供职腾讯、阿里巴巴。2014年创立零氪科技，建立智能标准化肿瘤数据平台，并已直接...
阅读更多 中电药明数据科技 首席执行官
Mr. Andy A. Liu is the CEO of CW Data Technologies. (中电药明数据科技)CW Data is a ...
阅读更多 神州数码医疗 副总裁
李洪博士现任神州数码医疗科技股份有限公司的副总裁。李博士也是美国辛辛那提(Cincinnati)大学药学院客座副教授以及中国上海交通大学公共卫生学院客...
阅读更多 科大讯飞副总裁， 科大讯飞医疗总裁
陶晓东，中国科学技术大学电子工程系学士，美国约翰霍普金斯大学博士，电子电气工程师学会（IEEE）高级会员，研究方向为医学影像。曾服务于美国通用电气公司...
阅读更多 将门创投 CEO、创始合伙人
高欣欣，现任将门CEO、将门创投创始合伙人。将门是一家专注于发掘、加速和投资技术创新激活商业价值的创业公司的创投机构。将门旗下设有对接标杆用户、技术垂...
阅读更多 云鹊医疗科技 首席执行官
Fay XING is the CEO of Pica Health, a digital health company that was incubated at Wuxi Healthcare Ventures. Pica is committed to empower Chinese phys...
阅读更多 东软熙康健康科技有限公司 首席运营官
侯宁，现任东软熙康健康科技有限公司高级副总裁兼首席运营官(COO)，主要负责东软熙康公司的业务咨询规划、市场拓展与联盟合作，以及运营服务模式开发与管理...
阅读更多 腾讯医疗健康 总经理
张猛，腾讯医疗副总裁。凭借对医疗行业深厚的热忱和经验，张猛于2016年12月加入腾讯，主要负责数字化医疗创新项目的孵化，目前已成功打造一款全新医学科普...
阅读更多 Dr. Ge Li is one of the most influential leaders in the global biopharma R&D industry. He pioneered an integrated R&D service model and the open-access R&D enabling platform model with the conviction that more efficient and cost-effective R&D should be at the core of better medicines for patients, and that “every drug can be made and every disease can be treated.” As the company’s Chairman, Dr. Li has led WuXi’s rapid growth from four employees and a single Chemistry lab of 7,000 square feet in December 2000 to a transformative global R&D powerhouse enabling over 3,000 collaborative partners worldwide. Dr. Li earned his Bachelor’s degree in Chemistry from Peking University and his doctoral degree in Organic Chemistry from Columbia University.
Steve Bates英国生物工业协会（BIA） 首席执行官 Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve sought to make the UK life science ecosystem the third global cluster.
陈之键阿斯利康 全球肿瘤研发高级副总裁、中国新药研发总裁 医学博士陈之键自2013年4月起加入阿斯利康中国，现担任全球肿瘤研发高级副总裁兼中国新药研发负责人。陈博士在药物研发领域有15年以上的管理经验，曾就职于临床研发、医学事务、战略策划和业务开发等各个部门。在加入阿斯利康前，陈之键先生曾在百济担任首席医学官，一家在中国致力于肿瘤药物研究和开发的生物科技药业公司。
Damian O’Connell新加坡科技研究局， Experimental Drug Development Centre 首席执行官 Most recently Damian was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Clinical Sciences (CS) is a global organization (based Germany, US, Japan, China) with responsibility for the first use of drug products in humans up to Proof of Concept, as well as all clinical pharmacological components of NDAs.
Dr. Steve Yang is Executive Vice President and Chief Business Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. His responsibilities include management of multiple business units and commercial operation. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device R&D capability and technology open access platform company with operations in China, US, and Europe.
何大一Aaron Diamond 艾滋病研究中心 科学主任兼首席执行官 David D. Ho is the founding Scientific Director of the Aaron Diamond AIDS Research Center and the Irene Diamond Professor at The Rockefeller University. He received his degrees from California Institute of Technology (1974) and Harvard Medical School (1978).
Zhijian ‘James’ Chen is an Investigator of Howard Hughes Medical Institute, and Professor in the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas. He is also Director of Inflammation Research Center and George L. MacGregor Distinguished Chair in Biomedical Science at UT Southwestern. Prior to moving to Dallas, Chen was a senior scientist at ProScript Inc. where he helped discover the proteasome inhibitor VELCADE, a medicine used for the treatment of multiple myeloma. After joining UT Southwestern in 1997, Chen discovered the regulatory role of ubiquitination in protein kinase activation in the NF-B and MAP kinase pathways. In addition, he discovered the Mitochondrial Antiviral Signaling (MAVS) protein that reveals a new role of mitochondria in immunity. More recently, Chen discovered cyclic GMP-AMP synthase (cGAS) as a cytosolic DNA sensor and a new cyclic di-nucleotide signaling pathway that mediate innate immune responses in animal cells. For his work, Chen has received numerous honors including the National Academy of Science Award in Molecular Biology (2012), the American Society of Biochemistry and Molecular Biology (ASBMB) Merck Award (2015), the Lurie Prize in Biomedical Sciences from the Foundation of NIH (2018) and the Breakthrough Prize in Life Sciences (2019). Chen is a member of the National Academy of Sciences.
Jane OsbournMedImmune研发副总裁， 英国工业协会主席 Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), now the global biologics research and development arm of AstraZeneca, in 1993. An expert in antibody engineering, she has authored many key publications and patents, and made a significant contribution to the discovery and development of a number of marketed drugs and more than 40 clinical candidates. She has worked across many therapy areas and currently leads a global team, based in Gaithersburg US, focused on the development of biosuperior antibody therapies. Jane is also Site Leader for MedImmune’s facility in Cambridge UK, which is home to over 550 MedImmune employees, and chairs the cross-campus leadership team for AstraZeneca in Cambridge.
梁颕宇女士是启明创投领导医疗健康行业投资的主管合伙人。启明目前旗下管理总基金规模超过43亿美元并投资了超过300家创新企业。
Ken DrazanArsenal Bio 联合创始人及首席执行官 Ken is the CEO and co-founder of Arsenal Bio, a startup focused on synthetic control of the immune system which is based in San Francisco and Los Angeles. Prior to Arsenal, Ken was a founding executive and President at GRAIL, co-founded Verb Surgical (J&J - Google Joint Venture), Medibis (business intelligence software in outpatient care), Arginox (cardiovascular drug discovery), and PMG Group (healthcare revenue cycle management). Ken co-founded Bertram Capital Management which has $1.4B under management. Prior to his business career, Ken was on the academic faculty of Stanford and UCLA as an academic liver transplant surgeon, researcher, and educator.
何如意博士在美国FDA具有17年临床审评审批经验, 主管消化系统胃肠道类药物及罕见病药物的临床审评审批工作，曾是美国FDA新药审批办公室消化系统及罕见病药物审评部代理付主任。他主持起草多个FDA的工业指南，包括药物诱导肝损伤的临床评价指南和肠易激综合征产品的临床评价指南等等。主持过上千个药企和FDA的工作技术交流会，负责审批了许多新药试验申请和新药上市申请并获得诸多奖项。 何如意博士2016年7月加入原中国食品药品监督管理总局（cFDA）药品审评中心（CDE），作为中国cFDA首位从外海引入的高级人才，担任首席科学家。在中国CDE期间，何如意博士与总局和中心领导一同开展中国整体审评审批体系和制度改革，组织技术指南撰写，组织培训，建立与美国FDA审评部门及美国监管研究机构的长期合作。将美国FDA审评审批理念引入CDE；与国际审评标准接轨；提倡监管服务理念；提高审评审批速度与质量。 近期，何如意博士加入了国投创新担任医疗健康首席科学家。 何如意博士毕业于中国医科大学，并获得医学学士学位和内科血液学硕士学位。于1988年3月赴美，在美国国家卫生研究院（NIH）从事临床研究，并在美国Howard大学医学院完成内科住院医师工作，目前持有美国多个州的执业医师证书。
John Oyler百济神州 创始人、董事长兼首席执行官 John V. Oyler is the Co-Founder, Chief Executive Officer and Chairman of the Board of Directors of BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, commercial-stage, research-based biotechnology company. Prior to founding BeiGene, Mr. Oyler served as President and Chief Executive Officer of BioDuro, a drug discovery outsourcing company in Beijing, which was acquired by Pharmaceutical Product Development Inc. with attractive returns in 2010. Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology, with funding from Otsuka. Mr. Oyler was previously Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. He has also served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company that grew to $1.7 billion in revenues. Mr. Oyler began his career as a management consultant at McKinsey & Company. He received his B.S. from the Massachusetts Institute of Technology and an MBA from Stanford University.
Craig Anderson中国乔治全球健康研究所所长， 新南威尔士大学教授 Dr. Anderson is Executive Director of The George Institute for Global Health in China, Senior Principal Research Fellow of the National Health and Medical Research Council (NHMRC) of Australia, and Professor of Neurology and Epidemiology at the University of New South Wales, in Sydney, Australia.
作为默沙东全球副总裁及默沙东中国研发总经理，李正卿博士负责北京研发中心的整体运营和战略方向的把控。李正卿博士带领的研发团队肩负着将创新药物和疫苗以最有效和快捷的方式满足中国病患需求和引领默克实验室在中国建立全球研发能力的使命。同时, 李正卿博士领导建立与外部科研机构，专业协会和行业伙伴的合作。在李正卿博士的带领下，在过去的七年里，中国研发中心实现飞速发展，目前有500余名科研人员，工作在临床研究，注册事务，临床试验运营，药物安全，项目管理，信息技术及科学, 生物统计，流行病学和数据管理等职能部门。
Matt Cooper英国国家健康研究所 业务发展主管 The National Institute for Health Research Clinical Research Network is the research delivery arm of the NHS. It invests some £300m each year into an infrastructure of clinical research professionals across England, to support rapid study set-up and patient recruitment into clinical research studies (academic and commercial). The Network has demonstrated year-on-year improvements in patient recruitment numbers and delivery times for commercial studies.
Dr. Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Dr. Firth founded ASLAN in 2010 after a career in global pharmaceutical firms and healthcare investment banking. ASLAN is the first Singaporean publicly listed biotech and is currently trading on NASDAQ and the Taipei Exchange.
Dr. James Xue has spent 20+ years in pharmaceutical industry and is the founder, chairman & CEO of CANbridge Pharmaceuticals Inc., a bio-tech company focused on oncology and rare disease. He holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He is deputy director general of China Alliance for Rare Disease (CARD), a R & D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA), a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School. He is a member of BayHelix Group and founding member of BayHelix Boston Chapter.
Alex ZhavoronkovInsilico Medicine 创始人及首席执行官 Dr. Zhavoronkov is the CEO of Insilico Medicine, a leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generation of the novel molecular structures with the desired properties and set up R&D centers in the UK, Russia, Hong Kong and Taiwan. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation. Since 2012 he published over 120 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Eric MorgenBIOAGE 首席运营官、首席医学官 Eric leads BIOAGE’s human cohort partnerships and computational efforts to discover and prioritize drug targets for human aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. Eric completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.
Sang Hoon LeeABL Bio 首席执行官 Sang Hoon Lee is the founder and CEO of ABL Bio. Prior to creating ABL Bio, Sang Hoon Lee served as the head of the Bio Division at Hanwha Chemical from 2013 to 2016. He also was the co-founder and CSO of PharmAbcine from 2009 to 2013. Sang Hoon Lee has strong entrepreneur and industry experience. He directed drug discovery and development at Exelixis, Genentech, AstraZeneca, and Chiron (now known as Novartis). Sang Hoon Lee received his B.A. and M.S. from the Seoul National University, his Ph.D. from The Ohio State University. He completed his postdoctoral fellow from Harvard Medical School and UCSF, and was a Scientist at Stanford Medical School.
Guy SpigelmanaMoon Fund 副总裁 Guy Spigelman is VP of Portfolio Success at aMoon, a Global HealthTech and LifeSciences VC based in Israel with over $800M under management. Previously, Guy served as CEO of PresenTense – a network of start-up accelerators that launches over 100 startups per years. In this role, Guy founded 7 new accelerator programs, including A3i – the first accelerator in the world focused on Assistive and Aging Technologies.
Ash BahlCarrick Therapeutics 首席科学官及研发负责人 Dr. Bahl has 25 years of international Pharmaceutical experience working to deliver innovation via drug development projects in the US, Japan, and Europe. His previous roles were with Eli Lilly (2011-2015 as Vice President of External Innovation and Venture partnering), AstraZeneca (1994-2011 Vice President Head of R&D New Opportunities) and Glaxo (1990-1994 Research Scientist).
Karen ReevesAZTherapies 总裁兼首席医学官 Karen Reeves, MD is President and Chief Medical Officer at AZTherapies, a start-up company using a multi-action approach to treat Alzheimer’s Disease and neuroinflammation with Harvard-based science. AZTherapies is currently conducting a global clinical trial in AD. Prior to joining AZTherapies in 2017, Dr. Reeves served at Pfizer under numerous leadership positions including VP Global Head of Clinical Submissions Quality and Innovation and VP Neuroscience Global Research and Development. Dr. Reeves also served as VP, Global Head of Medical Science at Astellas and represented Astellas in Brussels at EFPIA’s Scientific, Regulatory, and Manufacturing Committee.
潘峥婴北京大学深圳研究生院化学生物学与生物技术学院 特聘研究员 1994年毕业于北京大学化学系，1999年获得美国哥伦比亚大学博士学位（导师：Clark Still教授），2002年在斯坦福大学完成博士后研究（导师：Barry Trost教授）。随后在多个美国生物医药公司从事创新药物研发工作。2009年回国后，在北京大学深圳研究生院任课题组长，2013年获得药明康德生命化学研究奖学者奖。从事药物化学和化学生物学研究；致力于发展共价药物理论和技术体系，并运用于抗肿瘤和免疫功能调控的创新药物研究；化合物伊布替尼（商品名“亿珂”）的主要发明者之一。在J Med Chem、Angew Chieme、PNAS等国际学术刊物和著作中发表论文和章节二十余篇，获得美国、欧盟、中国等授权专利十余项。
Simone BottiMetabomed 首席执行官 Dr. Botti has been Metabomed's CEO since July 2016. Simone co-founded Metabomed while he was Head of the Israel Bioincubator Fund at Merck Ventures, which he joined in 2011. During his tenure at Merck Ventures, Dr. Botti set up the Israel Bioincubator Fund and established a number of early stage companies. Previously, he was Vice President, Business Development at RAD Biomed Accelerator, one of Israel's leading Life Science incubators. Prior to that, he was Senior Director of Business Development at Cogenics. He also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Dr. Botti holds a PhD in Chemistry from the Weizmann Institute of Science where he received the "Dov Elad" prize in Structural Biology and was NIH_ADDP Fellow at Northwestern University Medical School in Chicago.
乔爽Vivace Therapeutics 总裁兼首席执行官 Dr. Sofie Qiao is the founding president and CEO of Vivace Therapeutics. Prior to co-founding Vivace, she served as managing director of WuXi ventures, the corporate venture arm of WuXi AppTec. Dr. Qiao co-founded the chemistry-driven drug discovery company LEAD Therapeutics in 2006, assembled the management team and played a central role in raising $17 million in Series A financing. The company was acquired in 2010 by BioMarin for up to $97 million, primarily for its PARP inhibitor (Talazoparib), then in preclinical development, which has since been approved by the FDA. Dr. Qiao began her industry career at Genzyme as a medicinal chemist, and later moved into business roles with McKinsey & Company, Syrrx (now Takeda California) and Discovery Partners International (now Galapagos). She received her PhD in organic chemistry from Massachusetts Institute of Technology and A.B. in chemistry from Harvard University.
林彦妮博士是苏州克睿基因的首席技术官及联合创始人。她致力于应用基因工程学方法, 在新型医药和诊断领域中创造临床和生产流程的解决方案。她有9年以上在哺乳动物系统中使用 TALENs 和 CRISPR/Cas9工具进行基因改造并进行转化研发的经验。她现在领导多个转化研究和临床前项目，利用基因编辑工具为区域和全球未满足的医疗需求创造更好的细胞/基因治疗产品。
Jörg WeiserSchrödinger 常务董事 Dr. Weiser joined Schrödinger in 2002. He received his doctorate in Organic Chemistry from the Georg-August-University in Göttingen, Germany in 1996. He conducted post-doctoral research at Columbia University in New York from 1997 to 1999 and worked in the MacroModel team of Prof. Clark Still. He was co-founder and Managing Director of Anterio, a German consulting and research company established in 1999, prior to joining Schrödinger.
Misti UshioTARA Biosystems 首席执行官 Misti Ushio is the CEO of TARA Biosystems.
刘琦, 同济大学生物信息系教授，博士生导师。IEEE会员，ACM会员，中国计算机协会CCF高级会员（生物信息学专业组委员），中国人工智能学会会员 (生物信息学与人工生命专委会委员)，上海市启明星人才、浦江人才。获第七届吴文俊人工智能自然科学奖三等奖。获2018年药明康德生命化学奖。致力于计算机和生命科学的智能计算和机器学习的交叉研究, 目前基于人工智能和机器学习方法进行药物研发，肿瘤精准治疗以及基因编辑系统的优化设计等方向的研究和转化工作。在Genome Biology, Nature Communications, Clinical Pharmacology & Therapeutics, Trends in Biotechnology, Trends in Pharmacological Science, WIREs Computational Molecular Science, Bioinformatics, Briefings in Bioinformatics等期刊发表系列论文70余篇。开发了相应的生物数据挖掘平台20余项，申请和获批相关专利和软件著作权多项。和产业界开展了广泛合作。
Naheed KurjiCyclica 总裁兼首席执行官 Naheed Kurji is the President and CEO of Cyclica, a Toronto-based, venture-backed biotechnology company that has recently been named by Deep Knowledge Analytics as one of the top 20 AI in Pharma companies globally. At Cyclica, Naheed and his team are reshaping drug discovery by offering the pharmaceutical industry an integrated computational biophysics and AI-augmented platform that enhances how scientists design the best drugs for patients, not just for a single protein. Naheed focuses on strategy and corporate development activities to affect change in the pharmaceutical industry with a vision of reducing drug discovery cycle times and risk with a holistic in silico polypharmacology and structural pharmacogenomics first strategy. In his role at Cyclica, Naheed is a co-founder of The Alliance for Artificial Intelligence in Healthcare (AAIH), of which Naheed is 1 of 4 appointed Executive Officers. He is passionate about how people interact with technology to make more informed and faster decisions, and is dedicated to advance the responsible application of AI to healthcare problems. He is an experienced professional specialized in strategic planning, corporate finance and entrepreneurship, and has been featured in the Globe and Mail, CBC, Forbes, Vanity Fair, StartUp Health Magazine, WuXi Insider Perspective, and VentureBeat. Naheed is also a guest lecturer at various universities and is a graduate of the University of Toronto, Rotman School of Management where he obtained his MBA.
Willliam R. KellerColand Pharmaceuticals 董事长 Willliam Robert Keller joined Roche in Basel 1972 and served from 1974 to 2003 in several marketing and General Manager positions at Roche Group in South America and Asia. From 1994 to 2003 he oversaw and established Roche in China as General Manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. In 2003, he founded Keller Pharma Consultancy, a pharmaceutical consulting firm focusing on market entry strategies for foreign biotech companies into the China market. He has been Vice Chairman of the Shanghai Association of Enterprises with Foreign Investment (SAEFI) and Deputy General Manager of Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd.
陈力博士，华领医药技术（上海）有限公司董事长、创始人、首席执行官、首席科学官。陈力博士曾任罗氏研发中国有限公司首席科学官，拥有20多年新药研发创新及管理经验。陈力博士于2011年成立华领医药，以“患者为先、创新为本、良药为民”为宗旨，运用“中西合璧、联合创新”的新药研发运营模式和“高标准、高质量、创造高价值”的经营理念，在5年内华领医药的糖尿病全球原创新药HMS5552成功取得中美临床试验批件、完成四个临床I期和临床II期POC试验，并在2017年全球率先启动同类产品III期临床试验和药品上市计划，实现全球首创、中国首发。在此期间，成功完成2亿美元融资和中国新药创新公司建设。
Ray TabibiazarTwist Bioscience 高级副总裁 Ray is a seasoned executive, bringing his unique perspective as a clinician-scientist leading and growing start-up companies. He joins Twist Bioscience from Aravive Biologics (now Aravive, Inc.) where he was a Founder and the Executive Chairman of the Board. He remains a non-executive Director. Concurrently, he ran 526 Ventures, a strategic consulting company working with multiple public and private biopharmaceutical companies. Previously, he served as a venture partner at Bay City Capital LLC. Prior to his time at Bay City Capital, he held a number of executive positions in biotechnology companies including Chief Scientific Officer of Aviir and Vice President of Translational Research for VIA Pharmaceuticals. Before moving to industry, Ray was a practicing cardiologist and an Adjunct Clinical Instructor of Medicine at Stanford University. He received his MD from Harvard Medical School and trained as an internist and cardiologist at Stanford University, while also receiving finance education at Stanford Business School. He has received numerous honors and research awards, has authored several peer reviewed papers, and is an inventor on multiple patents.
Dan Wang, MD, is the Head of Johnson & Johnson Innovation, Asia Pacific. In this role, she is responsible for managing a portfolio of co-investments spanning across all three sectors of Johnson & Johnson and expanding the external networks within the innovation ecosystem.
Curtis Keith哈佛大学Blavatnik生物医学加速中心 首席科学官 Dr. Curtis Keith has served as Chief Scientific Officer of Harvard University’s Blavatnik Biomedical Accelerator (previously, Harvard Biomedical Accelerator Fund) since 2008. By providing financial and other support, the Accelerator helps bridge the gap between early-stage research emanating from Harvard labs and validated de-risked technologies that are ready for industry partnership.
Robert S. Sullivan加州大学圣地亚哥分校Rady商学院 院长 Robert S. Sullivan joined the Rady School of Management at UC San Diego as its founding dean in January 2003. Dr. Sullivan is an expert on entrepreneurship, knowledge management and operations management.
Toshio Fujimoto武田药品工业株式会社，武田湘南健康创新园区 总经理 Toshio Fujimoto, MD, MBA, is the General Manager of Shonan Health Innovation Park (iPark), a science park launched by Takeda Pharmaceutical Company Ltd in Shonan, Japan in April 2018. In his current role, Dr. Fujimoto provides strategic leadership and oversight for all key iPark activities, including development and execution of business and financial plans, coordination of site operations and services, tenant recruitment and management, and marketing and public relations activities. He implements the iPark's vision to be an open innovation ecosystem which builds meaningful collaborations with academia, biotech, pharma companies, and the government.
Greg ScottChinaBio 创始人及首席执行官 Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on cross-border investment and partnering, including the ChinaBio® Partnering Forum which draws over 1400 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He also is the current chair for the American Chamber of Commerce Healthcare Committee, and a prior board member of BayHelix Group. Greg is considered a leading expert on China’s life science industry and is frequently quoted in media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, BioCentury, and other industry publications. Headquartered in Shanghai, ChinaBio® has team members in San Diego, Palo Alto, and Basel, Switzerland.
蔡江南中欧国际工商学院 卫生管理与政策中心主任、经济学教授 蔡江南教授是中欧国际工商学院卫生管理与政策中心主任、经济学兼职教授。他在中国和美国的大学、咨询公司、和政府部门从事了二十多年的卫生经济和卫生政策的教学、研究和咨询工作，发表了大量有影响的研究成果。他参与了美国第一个（麻省）全民医疗保障制度改革方案的设计、实施和评价，以及中国新医改方案的研究工作。
李彬博士是汇桥资本LB医疗基金的创始人和首席投资官及汇桥资本集团的合伙人。在此之前，李博士于2008-2015担任国际著名投资银行摩根士丹利的董事总经理和高级研究分析师, 主管大中华区医疗行业的投资研究。李博士建立了摩根士丹利亚洲医疗行业团队，并在两家知名华尔街投资评选机构——"机构投资者" (“Institution Investor”) 和 “Greenwich”的投票评比中，连续多年被评为亚洲和中国最佳医药行业分析师。其中包括在"机构投资者＂的评选中连续七年蝉联亚洲第一医疗分析师（2008-2014）以及连续五年蝉联＂中国最佳医药分析师＂(2010-2014)，也曾在其它权威排行榜评选中（比如"Greenwich"和"Asiamoney") 多次夺冠，还在" 华尔街日报" 2011年最佳亚洲医药行业分析师评选中，靠着出色的选股能力被评为最佳分析师。
Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester. President, Mayo Clinic Laboratories.
发起创办山蓝资本，具有医疗专业基金发起、募资、团队组建、投资、投资后管理等全过程管理经验；
Martien van OschForbion 管理合伙人 Martien is a Managing Partner at Forbion, a leading European venture capital firm that works closely with entrepreneurs to build life sciences companies that transform people’s lives.
刘釜均博士深耕生命科学行业近30年，其中包括20年临床诊断及医疗设备跨国集团的领导经验，在跨文化业务与资源整合，新兴公司业务拓展，国际并购重组及企业管理等方面拥有丰富的经验。
Mr. Andy A. Liu is the CEO of CW Data Technologies. (中电药明数据科技)
Fay XING is the CEO of Pica Health, a digital health company that was incubated at Wuxi Healthcare Ventures. Pica is committed to empower Chinese physicians through education and services. Concurrently, Fay is a venture partner at 6 Dimensions Capital, where she invests and seeds early stage healthcare companies in both China and US. She has over ten years of experience investing and operating in healthcare companies in US and China. She graduated from Stanford Medical School and Harvard Business School.
